TICKERNERD
Menu
ALECALECHealthcare · Biotechnology

ALEC Stock Forecast: Alector, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.14
0.00% on the day

The 8 Wall Street analysts covering Alector, Inc. hold a median 12-month price target of $2 — -6.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$238.9M
Ticker Nerd rank
41 / 100
Median analyst target
$2.00
Analysts covering
8
Revenue$3.3M−57.8% y/y
Operating income−$24.4M
Net income−$23.0M
Free cash flow−$34.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.7%
1M
+2.4%
YTD
+37.2%
1Y
−25.4%
From 52W high
−35.5%
From 52W low
+87.7%
$1.14
$3.32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALEC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alector, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
66
Issuance
64
Revisions
63
Momentum
52
Accruals
44
Growth
37
Value
34
Volatility
30
Quality
30

Size (66): Smaller than most of the companies we track.

Quality (30): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALEC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALEC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26ALECHigh $6.00Median $2.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
3 Buy3 Hold2 Sell
Low $1.00Median $2.00High $6.00

The green dot is the last close — the median target sits −6.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Apr 2026Cantor FitzgeraldUpgradeOverweight—
10 Mar 2026BTIGUpgradeBuy—
22 Oct 2025BTIGDowngradeNeutral—
22 Oct 2025Cantor FitzgeraldDowngradeNeutral—
22 Oct 2025HC Wainwright & Co.MaintainsBuy—
22 Oct 2025TD CowenDowngradeHold—
22 Oct 2025William BlairDowngradeMarket Perform—
25 Sept 2025BTIGReiteratesBuy—
28 July 2025MizuhoUpgradeOutperform—
9 May 2025HC Wainwright & Co.MaintainsBuy—
7 Mar 2025Morgan StanleyAssumesUnderweight$3.00 → $1.50
27 Feb 2025HC Wainwright & Co.ReiteratesBuy—
16 Dec 2024StifelDowngradeHold—
26 Nov 2024BTIGMaintainsBuy—
26 Nov 2024Cantor FitzgeraldReiteratesOverweight—
26 Nov 2024Morgan StanleyDowngradeUnderweight—
7 Nov 2024HC Wainwright & Co.ReiteratesBuy—
17 Sept 2024Cantor FitzgeraldReiteratesOverweight—
9 Sept 2024Cantor FitzgeraldReiteratesOverweight—
29 July 2024Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALEC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ALEC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Alector, Inc. returned −25.4% against +17.5% for the S&P 500, dividends included.

ALEC vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26ALECS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALEC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
3
Fundamentals

Alector, Inc. (ALEC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.5×

Cheaper than 84% of US stocks

Price / sales
17.2×

Cheaper than 10% of US stocks

Price / book
−23.9×

Cheaper than 98% of US stocks

EV / EBITDA
−0.8×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
−57.8%

Higher than 5% of US stocks

Earnings growth (YoY)
−57.8%

Higher than 9% of US stocks

Gross margin
—
Operating margin
−734.7%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−385.1%

Higher than 4% of US stocks

Return on assets
−27.6%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alector, Inc. (ALEC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alector, Inc. has a market value of $238.9M and an enterprise value of $98.9M.

  • Revenue in the twelve months to 30 June 2026: $13.9M. The latest quarter shrank 57.8% year on year.

  • Net income over the same four quarters: −$117.9M, a −850.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.10.

  • Free cash flow in the twelve months to 30 June 2026: −$158.4M.

  • Shares outstanding: 111.7M.

  • Trailing P/E: −1.5×; forward P/E: −2.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Alector, Inc. employs 103 people — $135K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ALEC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALECAlector, Inc.$238.9M
41
CGENCompugen Ltd.$233.5M
81
WHWKWhitehawk Therapeutics, Inc.$234.3M
71
IVVDInvivyd, Inc.$231.4M
19
RNACCartesian Therapeutics, Inc.$240.0M
24
GLSIGreenwich LifeSciences, Inc.$226.8M
38
ELDNEledon Pharmaceuticals, Inc.$225.9M
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alector, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALEC news & analysis

Alector to Participate in Upcoming Healthcare Conferences

GlobeNewsWire · 3 Sept 2026neutral

Alector announced that management will participate in the upcoming Cantor Global Healthcare Conference 2026 in New York, scheduled for September 10, 2026 at 2:10 p.m. The announcement was made in a press release from South San Francisco on September 3, 2026.

Why it matters — Alector watchers would care because the conference appearance offers management a chance to present the company's neurodegenerative disease programs to investors and analysts.

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 7 Aug 2026positive

Alector reported a second-quarter loss of $0.21 per share, narrower than the Zacks Consensus Estimate of a $0.24 loss and an improvement over the $0.30 loss from the same period last year. The company also topped revenue estimates for the quarter.

Why it matters — ALEC watchers would note that the company beat earnings expectations and narrowed its year-over-year loss, a modest improvement in its financial performance.

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 6 Aug 2026positive

Alector reported its second quarter 2026 financial results and provided a business update. The company highlighted advancement of its ABC blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as its lead ABC-enabled anti-amyloid beta antibody program for Alzheimer's disease, alongside continued progress on AL064/AL164 (Tau siRNA) and AL050 (GCase enzyme replacement therapy for Parkinson's disease).

Why it matters — ALEC watchers would care because the update details pipeline progress across three of Alector's key ABC-enabled programs for Alzheimer's and Parkinson's diseases.

FAQ

Frequently asked questions about ALEC stock

What is the ALEC stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Alector, Inc. have a median 12-month price target of $2, with estimates ranging from $1 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALEC stock a buy right now?

Of the 8 analysts covering Alector, Inc., 3 rate it a Buy, 3 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Alector, Inc. 41 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALEC?

As at 12 Sept 2026, Alector, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (66 of 100).

Will ALEC stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies -6.5% from the last close, and Ticker Nerd's factor model ranks Alector, Inc. 41 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALEC stock forecast for 2030?

No analyst covering Alector, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALEC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $6 over the next 12 months.

How has ALEC stock performed over the past year?

Alector, Inc. returned -25.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alector, Inc. do?

Alector Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases.

What is the latest news on ALEC?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Alector to Participate in Upcoming Healthcare Conferences". Alector announced that management will participate in the upcoming Cantor Global Healthcare Conference 2026 in New York, scheduled for September 10, 2026 at 2:10 p.m. The announcement was made in a press release from South San Francisco on September 3, 2026.

Company

About Alector, Inc.

Alector Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. Alector Inc. applies its immuno-neurology platform to target the immune dysfunction and protein-related pathology associated with conditions such as Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia. The company’s current portfolio includes monoclonal antibody and other biologic programs designed to restore healthy immune function in the brain, supported by biomarker-guided clinical development. It also advances Alector Brain Carrier, a proprietary blood-brain barrier platform intended to improve therapeutic delivery to the central nervous system. Headquartered in South San Francisco, California, Alector Inc. operates as a research-driven biopharmaceutical company with a focus on translating genetics, immunology, and neuroscience into treatments for severe brain disorders.

CEO Dr. Arnon Rosenthal Ph.D. · 103 employees · United States · https://www.alector.com